|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1 Suppl
|
|
pubmed:dateCreated |
2006-7-5
|
|
pubmed:abstractText |
Cardiac tissue engineering aims at providing heart muscle for cardiac regeneration. Here, we hypothesized that engineered heart tissue (EHT) can be improved by using mixed heart cell populations, culture in defined serum-free and Matrigel-free conditions, and fusion of single-unit EHTs to multi-unit heart muscle surrogates.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Collagen,
http://linkedlifedata.com/resource/pubmed/chemical/Culture Media,
http://linkedlifedata.com/resource/pubmed/chemical/Culture Media, Serum-Free,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Growth Substances,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Laminin,
http://linkedlifedata.com/resource/pubmed/chemical/Proteoglycans,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Extracts,
http://linkedlifedata.com/resource/pubmed/chemical/Triiodothyronine,
http://linkedlifedata.com/resource/pubmed/chemical/matrigel
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
4
|
|
pubmed:volume |
114
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
I72-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16820649-Animals,
pubmed-meshheading:16820649-Animals, Newborn,
pubmed-meshheading:16820649-Capillaries,
pubmed-meshheading:16820649-Cells, Cultured,
pubmed-meshheading:16820649-Chick Embryo,
pubmed-meshheading:16820649-Collagen,
pubmed-meshheading:16820649-Culture Media,
pubmed-meshheading:16820649-Culture Media, Serum-Free,
pubmed-meshheading:16820649-Drug Combinations,
pubmed-meshheading:16820649-Endothelial Cells,
pubmed-meshheading:16820649-Fibroblasts,
pubmed-meshheading:16820649-Growth Substances,
pubmed-meshheading:16820649-Heart,
pubmed-meshheading:16820649-Horses,
pubmed-meshheading:16820649-Insulin,
pubmed-meshheading:16820649-Laminin,
pubmed-meshheading:16820649-Morphogenesis,
pubmed-meshheading:16820649-Myocardial Contraction,
pubmed-meshheading:16820649-Myocardium,
pubmed-meshheading:16820649-Myocytes, Cardiac,
pubmed-meshheading:16820649-Proteoglycans,
pubmed-meshheading:16820649-Rats,
pubmed-meshheading:16820649-Regeneration,
pubmed-meshheading:16820649-Serum,
pubmed-meshheading:16820649-Tissue Engineering,
pubmed-meshheading:16820649-Tissue Extracts,
pubmed-meshheading:16820649-Triiodothyronine
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle.
|
|
pubmed:affiliation |
Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistr. 5, 20246 Hamburg, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
